Lung cancer is one of the leading causes of death worldwide, with two main types of the disease - non-small cell lung malignancies and small cell lung cancer - accounting for approximately 85% and 15% of mortalities respectively. Like other diseases and infections, lung cancer can also be diagnosed by tumor markers that are produced by Lung cancer patients. Antibodies from five classes of antibodies are IgG, IgM, IgA, IgD, and IgE are produced against their own antigens known as autoantibodies, have their role in stopping or minimizing cancer, and play a vital role in diagnostic analysis of lung cancer. To diagnose lung cancer, a panel of six antibodies p53, CAGE, GBU4–5, NY-ESO-1, Annexin 1, and SOX2 has been studied to monitor lung cancer with a sensitivity of 38% and a specificity of 88 percent. Patients with lung cancer can produce p53 antibodies, an altered form of tumor suppressor known as Tp53. Other antibodies like NY-ESO 1, Annexin A1 and SOX2 can also be used as diagnostic biomarkers for the detection of lung cancer. In this review, we study all possible antitumor or Autoantibodies of lung cancer and their use in earlier detection of a lung cancer diagnosis.